



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/553,482	10/17/2005	Anne Catherine Morales	REGIM 3.3-067	1165
530	7590	10/23/2008	EXAMINER	
LERNER, DAVID, LITTENBERG, KRUMHOLZ & MENTLIK 600 SOUTH AVENUE WEST WESTFIELD, NJ 07090			THOMAS, DAVID C	
ART UNIT	PAPER NUMBER			
		1637		
MAIL DATE	DELIVERY MODE			
10/23/2008	PAPER			

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



UNITED STATES DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10553482	10/17/2005	MORALES ET AL.	REGIM 3.3-067
EXAMINER			
DAVID C. THOMAS			
ART UNIT		PAPER	
1637		101705-2	

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner for Patents**

The timely submission filed on July 31, 2008 includes a response to the restriction requirement of March 31, 2008. Applicant's election of Group I is acknowledged. However, there are several problems regarding the nucleotide sequences, as discussed in more detail below. In brief, these include failure to respond to the sequence restriction according to the Office Action of March 31, 2008. In addition, our sequence search office (STIC) has indicated that there is a problem with the disk containing the file of the sequence listing. Finally, the SEQ ID numbers cited in claim 15 appear to be identified incorrectly. Since the submission appears to be a bona fide attempt to provide a complete reply to the prior Office Action, Applicant is given a shortened statutory period of ONE MONTH or THIRTY DAYS from the mailing date of this letter, whichever is longer, to submit a complete reply. This shortened statutory period supersedes the time period set in the prior Office Action. This time period may be extended pursuant to 37 CFR 1.136(a).

Applicant failed to respond to the requirement to elect a single sequence from Group III, the individual SEQ ID NOS: 1 and 2 generic to claim 14. Election of a single sequence is required at this time.

The CRF Problem Report of June 7, 2007 indicates that something other than the sequence file was copied onto the disk (CRF, computer readable form). To perform a proper sequence search, a CRF containing the complete sequence listing is required. Applicant indicated in the letter of 5/8/2007 that a CRF containing the sequences was filed with a related PCT filing. However, our sequence search office has no record of a CRF for this PCT. Therefore, a new CRF with the sequence listing is required at this time.

Claim 15 cites the use of a primer pair consisting of SEQ ID NOS: 4 and 5. However, the sequence listing indicates SEQ ID NO: 4 is a synthetic cDNA of 161 nucleotides. Correction of the claims is requested.

David C. Thomas  
Patent Examiner  
Art Unit 1637

/Kenneth R Horlick/  
Primary Examiner, Art Unit 1637